Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure

American Heart Journal
Ferruccio De LorenzoVijay Vir Kakkar

Abstract

Congestive heart failure (CHF) is associated with a hypercoagulable state. A single-center, randomized, double-blind, placebo-controlled trial was performed to test the hypothesis that a prophylactic dose of low molecular weight heparin (bemiparin sodium 3500 IU/daily subcutaneously) will modify a hypercoagulable state in CHF. This study included 100 patients with CHF (New York Heart Association classification II to IV). All patients underwent 3 blood tests, at baseline (before randomization), 24 hours after randomization, and before hospital discharge or within 10 days from randomization. In comparison of baseline bemiparin sodium 3500 IU/daily subcutaneously with after 24 hours, there was a significant decrease in plasma levels of D-dimer (-13.8 ng/mL; P =.01) and prothrombin fragments 1 and 2 (-0.11 nmol/L; P =.01), whereas protein C was significantly increased (+3.5%; P =.03). In comparison of baseline bemiparin sodium 3500 IU/daily subcutaneously with after 4 to 10 days of therapy, there were significantly decreased plasma levels for factor VII:c (-3.0%; P =.01), D-dimer (-44.0 ng/mL; P =.002), and thrombin-antithrombin complex (-0.7 microg/L; P =.0001), whereas protein C was significantly increased (+16.0%; P =.03). On th...Continue Reading

Citations

Nov 28, 2012·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Gyanendra Kumar, Munish Kumar Goyal
Jul 11, 2006·American Heart Journal·Brandi J WittVéronique L Roger
Jul 14, 2006·International Journal of Cardiology·Sait Mesut DoganMehmet Serdar Kucukoglu
Oct 28, 2006·Journal of Thrombosis and Haemostasis : JTH·O Dotsenko, V V Kakkar
Feb 24, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Deepak ThataiPatrick M Pullicino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.